title: [Preliminary study of DA or HA regimen chemotherapy for the treatment of refractory and relapsed paroxysmal nocturnal hemoglobinuria].
abstract: OBJECTIVE
  To observe the efficacy and side effect of DA/HA regimen chemotherapy for the treatment of refractory and relapsed paroxysmal nocturnal hemoglobinuria (PNH).
  
  
  METHODS
  Eight patients with refractory and relapsed PNH were treated with DA/HA regimen chemotherapy. Three patients were treated with DA (DNR 40 mg/d, i.v.drip, the first and the second day; 20 mg/d, i.v.drip, the third day; Ara-C 100 mg/d, i.v.drip, for 5 days) and 5 patients with HA (HHT 2 - 3 mg/d, i.v.drip, for 5 days; Ara-C 100 mg/d, i.v.drip, for 5 days).
  
  
  RESULTS
  All the 8 patients responded well: the PNH clone was diminished in five patients. Hemolysis was remitted in 6 cases. Five patients showed improvement in hematological parameters. The dosage of corticosteroid was decreased in all of them. No serious side effect was revealed.
  
  
  CONCLUSIONS
  DA/HA regimen chemotherapy was safe and effective for refractory and relapsed PNH patients.
authors.affiliation: Institute of Hematology and Blood Diseases Hospital, CAMS and PUMC, Tianjin 300020, China.
authors.forename: Yan-ran
authors.initials: YR
authors.lastname: Cao
authors.forename: Zong-hong
authors.initials: ZH
authors.lastname: Shao
authors.forename: Hai-rong
authors.initials: HR
authors.lastname: Jia
authors.forename: Juan
authors.initials: J
authors.lastname: Sun
authors.forename: Hong
authors.initials: H
authors.lastname: Liu
authors.forename: Yu-hong
authors.initials: YH
authors.lastname: Wu
authors.forename: Tie-jun
authors.initials: TJ
authors.lastname: Qin
authors.forename: Jun
authors.initials: J
authors.lastname: Shi
authors.forename: Jie
authors.initials: J
authors.lastname: Bai
authors.forename: Guang-sheng
authors.initials: GS
authors.lastname: He
authors.forename: Rong
authors.initials: R
authors.lastname: Fu
authors.forename: Ming-feng
authors.initials: MF
authors.lastname: Zhao
authors.forename: Hai-feng
authors.initials: HF
authors.lastname: Tu
authors.forename: Zhen-zhu
authors.initials: ZZ
authors.lastname: Cui
authors.forename: Tian-ying
authors.initials: TY
authors.lastname: Yang
mesh_terms: D000293:Adolescent; D000328:Adult; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D017261:Glycosylphosphatidylinositols / Q000032:analysis; D006248:Harringtonines; D006457:Hemoglobinuria, Paroxysmal / Q000188:drug therapy*; D006801:Humans; D008297:Male
chemical_list: D017261:Glycosylphosphatidylinositols; D006248:Harringtonines; D003561:Cytarabine; C062500:harringtonin; D003630:Daunorubicin